Emerging Treatments for ESCC and Gastric/GEJ Adenocarcinoma

This discussion outlines several emerging therapeutic approaches currently under investigation for advanced gastric and gastroesophageal junction (GEJ) cancers. The discussion highlights ongoing development of antibody–drug conjugates (ADCs), including HER2-directed and Claudin 18.2-directed agents, which are being evaluated across multiple clinical trials. Early-phase studies of FGFR2b-targeted therapies, such as bemarituzumab, are also reviewed, with noted antitumor activity in biomarker-selected patient populations. The segment further describes exploratory immunotherapy combinations, such as those incorporating agents directed at LAG-3 or TIGIT, which are being assessed in clinical research settings. CAR T-cell therapies targeting gastric-specific antigens represent another area of early investigation, although current data remain preliminary. Throughout the discussion, the panel emphasizes the importance of molecular profiling to help identify candidates for these investigational approaches. As these studies progress, they may help inform future treatment strategies for advanced gastric and GEJ cancers.